Pre-treatment of rapamycin transformed M2 microglia alleviates traumatic cervical spinal cord injury via AIM2 signaling pathway in vitro and in vivo
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110394 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Xiao Xiao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, National Center for Neurological Disorders, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center…. Hauptthemen laut MEDLINE: Cervical Cord, Spinal Cord Injuries. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fudan University, Huashan Hospital.
Abstract (Originalsprache)
BACKGROUND: Traumatic spinal cord injury (SCI) is still devastating. It was suggested that the inhibition of mTOR may alleviate neuronal inflammatory injury but its underlying mechanism remained to be elucidated. AIM2 (absent in melanoma 2) recruits ASC (apoptosis-associated speck-like protein containing a CARD) and caspase-1 to form the AIM2 inflammasome, activate caspase-1, and elicit inflammatory responses. We designed this study to elucidate whether pre-treatments of rapamycin could suppress SCI induced neuronal inflammatory injury via AIM2 signaling pathway in vitro and in vivo. METHODS: We performed oxygen and glucose deprivation / re-oxygenation (OGD) treatment and rats clipping model to mimic neuronal injury after SCI in vitro and in vivo. Morphologic changes of injured spinal cord were detected by hematoxylin and eosin staining. The expression of mTOR, p-mTOR, AIM2, ASC, Caspase-1 and et al were analyzed by fluorescent staining, western blotting or qPCR. The polarization phenotype of microglia was identified by flow cytometry or fluorescent staining. RESULTS: We found BV-2 microglia without any pre-treatment cannot alleviate primary cultured neuronal OGD injury. However, pre-treated rapamycin in BV-2 cells could transform microglia to M2 phenotype and protects against neuronal OGD injury via AIM2 signaling pathway. Similarly, pre-treatment of rapamycin could improve the outcome of cervical SCI rats through AIM2 signaling pathway. CONCLUSIONS: It was suggested that resting state microglia pre-treated by rapamycin could protect against neuronal injury via AIM2 signaling pathway in vitro and in vivo. Pre-inhibition of mTOR pathway may improve neuronal protection after SCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, National Center for Neurological Disorders, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center of Neurosurgery, Shanghai Key Laboratory of Brain Function and Restor…
Förderung
- National Natural Science Foundation of China
- Fudan University
- Huashan Hospital
- National Key Research and Development Program of China
Zitieren
APA
Xiao, X., Chen, X. Y., Dong, Y. H., Dong, H. R., Zhou, L. N., Ding, Y. Q., Chen, G., Zhao, J. L., & Xie, R. (2023). Pre-treatment of rapamycin transformed M2 microglia alleviates traumatic cervical spinal cord injury via AIM2 signaling pathway in vitro and in vivo. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110394
Vancouver
Xiao X, Chen XY, Dong YH, Dong HR, Zhou LN, Ding YQ, et al. Pre-treatment of rapamycin transformed M2 microglia alleviates traumatic cervical spinal cord injury via AIM2 signaling pathway in vitro and in vivo. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110394
BibTeX
@article{Xiao2023,
author = {Xiao, Xiao and Chen, Xing-Yu and Dong, Yin-Hui and Dong, Hao-Ru and Zhou, Long-Nian and Ding, Yuan-Qing and Chen, Gong and Zhao, Jian-Lan and Xie, Rong},
title = {Pre-treatment of rapamycin transformed M2 microglia alleviates traumatic cervical spinal cord injury via AIM2 signaling pathway in vitro and in vivo},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110394}
}
EUVIMED